الفهرس | Only 14 pages are availabe for public view |
Abstract Low dose Aspirin use with patients that have unresectable HCC intermediate stage undergoing TACE is feasible, tolerable, inexpensive and may improve overall and progression free survival, we encourage further prospective trials in the future as role of aspirin not well defined. |